Baxter International Inc.
$25.39$0.00 (0.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $10.0B
- P/E
- -10.4x
- EV / EBITDA
- 23.2x
- Revenue
- $11.2B
- Net margin
- -8.5%
- ROCE
- 1.0%
Price chart
Technical chartScreen technicals →+45.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +3.6%
- 3M
- -3.9%
- 6M
- +35.3%
- 1Y
- +45.8%
- 5Y
- -68.0%
52-week range
Day change $0.00 (0.0%) from $25 to $25 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BAX, bought on each weekday since 2021.
News & filings
What Baxter International filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 957 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are 2.31 times current liabilities.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Read moreShow less
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Shares outstanding
- 514.3M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $10.0B
- P/E
- -10.4x
- P/B
- 1.6x
- EV / EBITDA
- 23.2x
- EV / Sales
- 1.6x
- P/S
- 0.9x
- 52-week high
- $28.35
- 52-week low
- $15.80
Profitability
- Operating margin
- 1.6%
- Net margin
- -8.5%
- EBITDA margin
- 6.8%
- ROE
- -15.6%
- ROCE
- 1.0%
- ROA
- -4.8%
- Asset turnover
- 0.56
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $11.2B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 5.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 3.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 47.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $323.0M
Solvency
- Current ratio
- 2.31
- Debt / Equity
- 1.60
- Debt / Assets
- 0.49
- CFO / Net profit
- -0.88
- Cash / Market cap
- 19.7%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $11.2B |
| Cost of revenue | $7.9B |
| Gross profit | $3.4B |
| Operating expenses | $3.2B |
| Research and development | $518.0M |
| Selling, general and administrative | $2.9B |
| Operating income | $177.0M |
| Interest and other | -$682.0M |
| Pretax income | -$505.0M |
| Tax and other | $452.0M |
| Net income | -$957.0M |
Revenue and net profit
Revenue grew 5.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $10.1B | -$2.4B |
| FY2023 | $10.4B | $2.7B |
| FY2024 | $10.6B | -$649.0M |
| FY2025 | $11.2B | -$957.0M |
Cash flows
FY2025: $845.0M from operations, $323.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $1.2B | $576.0M |
| FY2023 | $1.7B | $1.3B |
| FY2024 | $1.0B | $559.0M |
| FY2025 | $845.0M | $323.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $11.2B+5.7%1Y
- EBITDA
- $766.0M-31.4%1Y
- Net profit
- -$957.0M
- Cash from operations
- $845.0M-17.1%1Y
- Free cash flow
- $323.0M-42.2%1Y
- Revenue CAGR, 3Y
- 3.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $11.2B | $766.0M | -$957.0M | $323.0M | -15.6% | +5.7% | +47.5% |
Monthly returns
Month-by-month returns of BAX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $20.1B |
| Current assets | $6.9B |
| Non-current assets | $13.2B |
| Liabilities | $14.0B |
| Current liabilities | $3.0B |
| Non-current liabilities | $11.0B |
| Equity | $6.1B |
| Paid-in capital | $6.4B |
| Retained earnings | $13.7B |
| Treasury stock | $10.9B |
| Minority interest | -$27.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BAX highlighted.
P/E against peers
BAX has no positive P/E; the peer median is 47.4x.
Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Baxter International Inc.BAXthis company | $10.0B | -10.4x | 1.6x | -15.6% | 23.2x |
| Revvity, Inc.RVTY | $11.4B | 47.4x | 1.6x | 3.3% | 18.2x |
| BrightSpring Health Services, Inc.BTSG | $11.3B | 59.4x | 6.0x | 10.2% | 30.3x |
| Molina Healthcare, Inc.MOH | $10.0B | 21.3x | 2.5x | 11.6% | — |
| Krystal Biotech, Inc.KRYS | $9.1B | 44.3x | 7.4x | 16.8% | 51.2x |
| Charles River Laboratories International, Inc.CRL | $8.9B | — | 2.8x | -4.6% | 27.5x |
| Henry Schein, Inc.HSIC | $8.7B | 21.8x | 2.7x | 12.3% | 12.4x |
| Bio-Techne CorporationTECH | $8.3B | 113.5x | 4.3x | 3.8% | 39.7x |
| Corcept Therapeutics IncorporatedCORT | $8.0B | 80.7x | 12.4x | 15.4% | 66.1x |
| Peer median | — | 47.4x | 3.6x | 10.9% | 30.3x |
Year-to-date ROI
BAX since 1 January, against earlier years.
Historical volatility
BAX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -0.3% |
| FY2023 | 6.8% |
| FY2024 | 4.1% |
| FY2025 | 1.6% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $11.2B |
| Cost of revenueCost Of Revenue | $7.9B |
| Gross profitGross Profit | $3.4B |
| Operating expensesOperating Expense | $3.2B |
| Research and developmentResearch And Development | $518.0M |
| Selling, general and administrativeSelling General And Administration | $2.9B |
| Other operating expensesOther Operating Expenses | -$206.0M |
| Total expensesTotal Expenses | $11.1B |
| Operating incomeOperating Income | $177.0M |
| Interest and other | |
| Pretax incomePretax Income | -$505.0M |
| TaxTax Provision | $395.0M |
| Net incomeNet Income | -$957.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $20.1B |
| Current assetsCurrent Assets | $6.9B |
| Non-current assetsTotal Non Current Assets | $13.2B |
| LiabilitiesTotal Liabilities Net Minority Interest | $14.0B |
| Current liabilitiesCurrent Liabilities | $3.0B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $11.0B |
| EquityTotal Equity Gross Minority Interest | $6.1B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $845.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $951.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$900.0M |
| Depreciation and amortisationDepreciation And Amortization | $981.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $981.0M |
| Depreciation | $383.0M |
| Amortization cash flowAmortization Cash Flow | $598.0M |
| Amortization of intangiblesAmortization Of Intangibles | $598.0M |
| Stock-based compensationStock Based Compensation | $117.0M |
| Deferred taxDeferred Tax | $77.0M |
| Deferred income taxDeferred Income Tax | $77.0M |
| Operating gains and lossesOperating Gains Losses | -$48.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | — |
| Asset impairmentAsset Impairment Charge | $802.0M |
| Pension and employee benefit expensePension And Employee Benefit Expense | -$32.0M |
| Change in working capitalChange In Working Capital | -$108.0M |
| Other non-cash itemsOther Non Cash Items | $30.0M |
| Cash from discontinued operating activitiesCash From Discontinued Operating Activities | -$106.0M |
| Investing cash flowInvesting Cash Flow | $2.8B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$464.0M |
| Capital expenditureCapital Expenditure | -$522.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$513.0M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | -$9.0M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$9.0M |
| Other investing changesNet Other Investing Changes | $58.0M |
| Cash from discontinued investing activitiesCash From Discontinued Investing Activities | $3.3B |
| Financing cash flowFinancing Cash Flow | -$4.2B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$4.2B |
| Debt issuedIssuance Of Debt | $2.0B |
| Debt repaidRepayment Of Debt | -$5.8B |
| Net debt issuedNet Issuance Payments Of Debt | -$3.8B |
| Short-term debt issuedShort Term Debt Issuance | $0.00 |
| Short-term debt repaidShort Term Debt Payments | -$300.0M |
| Net short-term debt issuedNet Short Term Debt Issuance | -$300.0M |
| Long-term debt issuedLong Term Debt Issuance | $2.0B |
| Long-term debt repaidLong Term Debt Payments | -$5.5B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$3.5B |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | $30.0M |
| Dividends paidCash Dividends Paid | -$348.0M |
| Common dividends paidCommon Stock Dividend Paid | -$348.0M |
| Other financing chargesNet Other Financing Charges | -$107.0M |
| Change in cashChanges In Cash | -$530.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 8,400.0% |
| Cash at the start of the yearBeginning Cash Position | $2.4B |
| Cash at the end of the yearEnd Cash Position | $2.0B |
| Free cash flowFree Cash Flow | $323.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Baxter International Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Leverage RatiosDebt/Equity of 1.60 is elevated, understand what that means for solvency.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read